A Pill That Blocks Measles Before It Spreads

Researchers at Georgia State University have developed an experimental oral antiviral that prevented a measles-like virus from spreading between ferrets through both close contact and the air — a potential breakthrough for containing one of the world's most contagious diseases.

The findings, published today in Nature Microbiology, come from the Center for Translational Antiviral Research (CTAR). The drug candidate, called GHP-88310, is a broad-spectrum inhibitor of the viral polymerase — the enzyme the virus needs to reproduce.

Two Routes of Transmission Blocked

The team tested whether giving the drug shortly before or after exposure could prevent transmission through direct contact or shared air. GHP-88310 successfully blocked both forms of spread.

"We designed the study to recapitulate viral spread between people with direct contact, for instance in a household, and between more distant social contacts, for example in classrooms," said senior author Richard Plemper, a Regents' Professor and director of the CTAR.

When the drug was used to treat animals already infected, it also reduced the length of time they remained contagious — a finding that could help shorten the severe social and economic burden of prolonged quarantine.

"We were very excited to see that GHP-88310 given by mouth completely prevented airborne transmission," said first author Carolin Lieber. "This finding is unprecedented for a viral polymerase inhibitor."

Measles Is Back

The breakthrough comes at a critical moment. Since 2025, measles has reemerged in the United States, causing thousands of infections across several states, hundreds of hospitalizations, and three confirmed deaths. Canada and Mexico have also experienced major outbreaks involving multiple deaths, raising concerns about whether North America can maintain its measles elimination status.

Vaccination remains the primary defense, but the MMR vaccine requires two doses and takes weeks to confer full protection. An oral antiviral that works immediately — taken as a prophylactic after exposure — could serve as a powerful complement, especially in outbreak settings like schools, hospitals, and households.

Toward Human Trials

The researchers are now preparing GHP-88310 for formal clinical trials. The drug's predecessor was described earlier this year in Science Advances, and the team has characterized its broad-spectrum activity against measles and related respiratory paramyxoviruses.

"Silencing measles outbreaks quickly is essential to reestablish control over the virus," Plemper said. "This study demonstrates that the drug is suitable to augment traditional ring vaccination against measles."

Why It Matters

Measles is one of the most contagious viruses known — a single infected person can infect 12-18 others in a susceptible population. Outbreaks require costly ring vaccination campaigns, contact tracing, and quarantines. An oral antiviral that can be deployed rapidly could transform outbreak response, particularly in communities with vaccination gaps.

The research was supported by the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH).

Sources